|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 December 2000, Vol. 96, No. 12, pp. 3671-3674
PERSPECTIVE
Report of an international working group to standardize response
criteria for myelodysplastic syndromes
Bruce D. Cheson,
John M. Bennett,
Hagop Kantarjian,
Antonio Pinto,
Charles A. Schiffer,
Stephen D. Nimer,
Bob Löwenberg,
Miroslav Beran,
Theo M. de Witte,
Richard M. Stone,
Moshe Mittelman,
Guillermo F. Sanz,
Pierre W. Wijermans,
Steven Gore, and
Peter L. Greenberg
From the National Cancer Institute, Bethesda, MD;
University of Rochester Cancer Center, Rochester, NY; MD Anderson
Cancer Center, University of Texas, Houston, TX; Centro di Riferimento
Oncologico, Aviano, Italy; Karmanos Cancer Center, Wayne State
University, Detroit, MI; Memorial Sloan-Kettering Cancer Center, New
York, NY; University Hospital, Rotterdam, The Netherlands; University
Hospital Nijmegen, Rijmegen, The Netherlands; Dana Farber Cancer
Institute, Boston, MA; Rabin Medical Center-Hasharon Hospital,
Petah-Tikva Tel-Aviv University, Tel-Aviv, Israel; Hospital
Universitario La Fe, Valencia, Spain; Ziekenhuis, Leyenburg,
The Hague, The Netherlands; Johns Hopkins Oncology Center, Baltimore,
MD; Stanford University Medical Center and Veterans Administration
Hospital, Palo Alto, CA.
Standardized criteria for assessing response are essential to
ensure comparability among clinical trials for patients with myelodysplastic syndromes (MDS). An international working group of
experienced clinicians involved in the management of patients with MDS
reviewed currently used response definitions and developed a uniform
set of guidelines for future clinical trials in MDS. The MDS differ
from many other hematologic malignancies in their chronicity and the
morbidity and mortality caused by chronic cytopenias, often without
disease progression to acute myeloid leukemia. Whereas response rates
may be an important endpoint for phase 2 studies of new agents and may
assist regulatory agencies in their evaluation and approval processes,
an important goal of clinical trials in MDS should be to prolong
patient survival. Therefore, these response criteria reflected 2 sets
of goals in MDS: altering the natural history of the disease and
alleviating disease-related complications with improved quality of
life. It is anticipated that the recommendations presented will require
modification as more is learned about the molecular biology and
genetics of these disorders. Until then, it is hoped these guidelines
will serve to improve communication among investigators and to ensure
comparability among clinical trials.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letters in Blood Online:
-
Clarifications to the standard neutrophil response criteria for clinical trials in myelodysplastic syndromes are needed
- David P. Steensma, Louis Letendre, Ayalew Tefferi, Bruce D. Cheson, John M. Bennett, and Peter L. Greenberg
Blood 2001 97: 3321-3322.
[Full Text]
[PDF]
-
Improve or abandon the standardized response criteria for myelodysplastic syndromes recommended by the International Working Group
- Azra Raza
Blood 2001 98: 251.
[Full Text]
[PDF]
-
Myelodysplastic syndromes standardized response criteria: further definition
- Bruce D. Cheson, John M. Bennett, Hagop Kantarjian, Charles A. Schiffer, Stephen D. Nimer, Bob Löwenberg, Richard M. Stone, Moshe Mittelman, Guillermo F. Sanz, Pierre W. Wijermans, and Peter L. Greenberg
Blood 2001 98: 1985-1986.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
T. E. Fandy, J. G. Herman, P. Kerns, A. Jiemjit, E. A. Sugar, S.-H. Choi, A. S. Yang, T. Aucott, T. Dauses, R. Odchimar-Reissig, et al.
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
Blood,
September 24, 2009;
114(13):
2764 - 2773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Sekeres and D. P. Steensma
Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment
Blood,
September 24, 2009;
114(13):
2575 - 2580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Greenberg, Z. Sun, K. B. Miller, J. M. Bennett, M. S. Tallman, G. Dewald, E. Paietta, R. van der Jagt, J. Houston, M. L. Thomas, et al.
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Blood,
September 17, 2009;
114(12):
2393 - 2400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma, M. R. Baer, J. L. Slack, R. Buckstein, L. A. Godley, G. Garcia-Manero, M. Albitar, J. S. Larsen, S. Arora, M. T. Cullen, et al.
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
J. Clin. Oncol.,
August 10, 2009;
27(23):
3842 - 3848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Voso, V. Santini, C. Finelli, P. Musto, E. Pogliani, E. Angelucci, G. Fioritoni, G. Alimena, L. Maurillo, A. Cortelezzi, et al.
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes
Clin. Cancer Res.,
August 1, 2009;
15(15):
5002 - 5007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Raza, N. Galili, S. Smith, J. Godwin, J. Lancet, M. Melchert, M. Jones, J. G. Keck, L. Meng, G. L. Brown, et al.
Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome
Blood,
June 25, 2009;
113(26):
6533 - 6540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Ma, U. Lim, Y. Park, S. T. Mayne, R. Wang, P. Hartge, A. R. Hollenbeck, and A. Schatzkin
Obesity, Lifestyle Factors, and Risk of Myelodysplastic Syndromes in a Large US Cohort
Am. J. Epidemiol.,
June 15, 2009;
169(12):
1492 - 1499.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Lyons, T. M. Cosgriff, S. S. Modi, R. H. Gersh, J. D. Hainsworth, A. L. Cohn, H. J. McIntyre, I. J. Fernando, J. T. Backstrom, and C.L. Beach
Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
J. Clin. Oncol.,
April 10, 2009;
27(11):
1850 - 1856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. Alessandrino, M. G. Della Porta, A. Bacigalupo, M. T. Van Lint, M. Falda, F. Onida, M. Bernardi, A. P. Iori, A. Rambaldi, R. Cerretti, et al.
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
Blood,
August 1, 2008;
112(3):
895 - 902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Sloand, C. O. Wu, P. Greenberg, N. Young, and J. Barrett
Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy
J. Clin. Oncol.,
May 20, 2008;
26(15):
2505 - 2511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Rizzieri, E. Feldman, J. F. DiPersio, N. Gabrail, W. Stock, R. Strair, V. M. Rivera, M. Albitar, C. L. Bedrosian, and F. J. Giles
A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
Clin. Cancer Res.,
May 1, 2008;
14(9):
2756 - 2762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Klisovic, W. Stock, S. Cataland, M. I. Klisovic, S. Liu, W. Blum, M. Green, O. Odenike, L. Godley, J. V. Burgt, et al.
A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia
Clin. Cancer Res.,
April 15, 2008;
14(8):
2444 - 2449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Park, S. Grabar, C. Kelaidi, O. Beyne-Rauzy, F. Picard, V. Bardet, V. Coiteux, G. Leroux, P. Lepelley, M.-T. Daniel, et al.
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
Blood,
January 15, 2008;
111(2):
574 - 582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Raza, J. A. Reeves, E. J. Feldman, G. W. Dewald, J. M. Bennett, H. J. Deeg, L. Dreisbach, C. A. Schiffer, R. M. Stone, P. L. Greenberg, et al.
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
Blood,
January 1, 2008;
111(1):
86 - 93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Haase, U. Germing, J. Schanz, M. Pfeilstocker, T. Nosslinger, B. Hildebrandt, A. Kundgen, M. Lubbert, R. Kunzmann, A. A. N. Giagounidis, et al.
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
Blood,
December 15, 2007;
110(13):
4385 - 4395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Ross, I. E. Allen, C. A. Probst, B. Sercus, S. M. Crean, and G. Ranganathan
Efficacy and Safety of Erythropoiesis-Stimulating Proteins in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis
Oncologist,
October 1, 2007;
12(10):
1264 - 1273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Introna, G. Borleri, E. Conti, M. Franceschetti, A. M. Barbui, R. Broady, E. Dander, G. Gaipa, G. D'Amico, E. Biagi, et al.
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study
Haematologica,
July 1, 2007;
92(7):
952 - 959.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Giles, D. Rizzieri, J. Karp, N. Vey, F. Ravandi, S. Faderl, K. Dad Khan, G. Verhoef, P. Wijermans, A. Advani, et al.
Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia
J. Clin. Oncol.,
January 1, 2007;
25(1):
25 - 31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Pelizzari, M. Drera, M. D'Adda, M. Ungari, D. Marocolo, F. Facchetti, D. Bellotti, S. Barlati, and G. Rossi
Recombinant granulocyte-colony stimulating factor as treatment for poor prognosis oligoblastic acute myeloid leukemia in elderly patients
Haematologica,
January 1, 2007;
92(1):
106 - 109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kantarjian, Y. Oki, G. Garcia-Manero, X. Huang, S. O'Brien, J. Cortes, S. Faderl, C. Bueso-Ramos, F. Ravandi, Z. Estrov, et al.
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Blood,
January 1, 2007;
109(1):
52 - 57.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Lyons, T. Cosgriff, S. Modi, H. McIntyre, C.L. Beach, and J. T. Backstrom
Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
2662 - 2662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. List, G. Dewald, J. Bennett, A. Giagounidis, A. Raza, E. Feldman, B. Powell, P. Greenberg, D. Thomas, R. Stone, et al.
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
N. Engl. J. Med.,
October 5, 2006;
355(14):
1456 - 1465.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cimino, F. Lo-Coco, S. Fenu, L. Travaglini, E. Finolezzi, M. Mancini, M. Nanni, A. Careddu, F. Fazi, F. Padula, et al.
Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia.
Cancer Res.,
September 1, 2006;
66(17):
8903 - 8911.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W.L. Yee, Z. Zeng, M. Konopleva, S. Verstovsek, F. Ravandi, A. Ferrajoli, D. Thomas, W. Wierda, E. Apostolidou, M. Albitar, et al.
Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Clin. Cancer Res.,
September 1, 2006;
12(17):
5165 - 5173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Silverman, D. R. McKenzie, B. L. Peterson, J. F. Holland, J. T. Backstrom, C.L. Beach, and R. A. Larson
Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
J. Clin. Oncol.,
August 20, 2006;
24(24):
3895 - 3903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson, P. L. Greenberg, J. M. Bennett, B. Lowenberg, P. W. Wijermans, S. D. Nimer, A. Pinto, M. Beran, T. M. de Witte, R. M. Stone, et al.
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Blood,
July 15, 2006;
108(2):
419 - 425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Nimer
Clinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5q
J. Clin. Oncol.,
June 1, 2006;
24(16):
2576 - 2582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Schiller, J. Slack, J. D. Hainsworth, J. Mason, M. Saleh, D. Rizzieri, D. Douer, and A. F. List
Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes
J. Clin. Oncol.,
June 1, 2006;
24(16):
2456 - 2464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Vey, A. Bosly, A. Guerci, W. Feremans, H. Dombret, F. Dreyfus, D. Bowen, A. Burnett, M. Dennis, V. Ribrag, et al.
Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study
J. Clin. Oncol.,
June 1, 2006;
24(16):
2465 - 2471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Stone
Is Intravenous Arsenic Trioxide a Useful Therapy in Myelodysplastic Syndromes?
J. Clin. Oncol.,
June 1, 2006;
24(16):
2414 - 2416.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Boula, M. Voulgarelis, S. Giannouli, G. Katrinakis, M. Psyllaki, C. Pontikoglou, F. Markidou, G. D. Eliopoulos, and H. A. Papadaki
Effect of cA2 Anti-Tumor Necrosis Factor-{alpha} Antibody Therapy on Hematopoiesis of Patients with Myelodysplastic Syndromes.
Clin. Cancer Res.,
May 15, 2006;
12(10):
3099 - 3108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A.N. Giagounidis, U. Germing, and C. Aul
Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid Malignancies
Clin. Cancer Res.,
January 1, 2006;
12(1):
5 - 10.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Fenaux and C. Kelaidi
Treatment of the 5q- Syndrome
Hematology,
January 1, 2006;
2006(1):
192 - 198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma and J. M. Bennett
The Myelodysplastic Syndromes: Diagnosis and Treatment
Mayo Clin. Proc.,
January 1, 2006;
81(1):
104 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Stasi, E. Abruzzese, G. Lanzetta, E. Terzoli, and S. Amadori
Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
Ann. Onc.,
December 1, 2005;
16(12):
1921 - 1927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Silverman, D. R. McKenzie, B. L. Peterson, R. M. Stone, B. L. Powell, C. Mayo, J. T. Backstrom, R. A. Larson, and The Cancer Leukemia Group B (CALGB)
Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
1848 - 1848.
[Abstract]
|
|
|
|
|
|
|
R. Lyons, T. Cosgriff, S. Modi, L. Lintz, C.L. Beach, and J. T. Backstrom
Azacitidine (Vidaza(R)) Treatment Response Assessed Using Three Alternative Dosing Schedules in Patients with Myelodysplastic Syndromes (MDS).
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
2517 - 2517.
[Abstract]
|
|
|
|
|
|
|
L. R. Silverman, D. R. McKenzie, B. L. Peterson, C. M. De Castro, J. Ellerton, K. N. Knapp, C.L. Beach, R. A. Larson, and The Cancer Leukemia Group B (CALGB).
Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
2526 - 2526.
[Abstract]
|
|
|
|
|
|
|
G. Barosi, D. Bordessoule, J. Briere, F. Cervantes, J.-L. Demory, B. Dupriez, H. Gisslinger, M. Griesshammer, H. Hasselbalch, R. Kusec, et al.
Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)
Blood,
October 15, 2005;
106(8):
2849 - 2853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jadersten, S. M. Montgomery, I. Dybedal, A. Porwit-MacDonald, and E. Hellstrom-Lindberg
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
Blood,
August 1, 2005;
106(3):
803 - 811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kaminskas, A. Farrell, S. Abraham, A. Baird, L.-S. Hsieh, S.-L. Lee, J. K. Leighton, H. Patel, A. Rahman, R. Sridhara, et al.
Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes
Clin. Cancer Res.,
May 15, 2005;
11(10):
3604 - 3608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma and A. F. List
Genetic Testing in the Myelodysplastic Syndromes: Molecular Insights Into Hematologic Diversity
Mayo Clin. Proc.,
May 1, 2005;
80(5):
681 - 698.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Cortes, S. Faderl, E. Estey, R. Kurzrock, D. Thomas, M. Beran, G. Garcia-Manero, A. Ferrajoli, F. Giles, C. Koller, et al.
Phase I Study of BMS-214662, a Farnesyl Transferase Inhibitor in Patients With Acute Leukemias and High-Risk Myelodysplastic Syndromes
J. Clin. Oncol.,
April 20, 2005;
23(12):
2805 - 2812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. List, S. Kurtin, D. J. Roe, A. Buresh, D. Mahadevan, D. Fuchs, L. Rimsza, R. Heaton, R. Knight, and J. B. Zeldis
Efficacy of Lenalidomide in Myelodysplastic Syndromes
N. Engl. J. Med.,
February 10, 2005;
352(6):
549 - 557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-M. Tsimberidou, F. J. Giles, I. Khouri, C. Bueso-Ramos, S. Pilat, D. A. Thomas, J. Cortes, and R. Kurzrock
Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience
Ann. Onc.,
January 1, 2005;
16(1):
139 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Patton, Y. Mun, and J. Wallace
Darbepoetin alfa Maintains Hemoglobin Levels in Patients with Myelodysplastic Syndromes (MDS) after Therapeutic Interchange from Epoetin alfa: Results of a Retrospective Chart Review.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
4708 - 4708.
[Abstract]
|
|
|
|
|
|
|
R. Stasi, M. Brunetti, E. Terzoli, E. Abruzzese, and S. Amadori
Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing
Ann. Onc.,
November 1, 2004;
15(11):
1684 - 1690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kuendgen, C. Strupp, M. Aivado, A. Bernhardt, B. Hildebrandt, R. Haas, U. Germing, and N. Gattermann
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid
Blood,
September 1, 2004;
104(5):
1266 - 1269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Casadevall, P. Durieux, S. Dubois, F. Hemery, E. Lepage, M.-C. Quarre, G. Damaj, S. Giraudier, A. Guerci, G. Laurent, et al.
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial
Blood,
July 15, 2004;
104(2):
321 - 327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Giannouli, M. Voulgarelis, E. Zintzaras, A. G. Tzioufas, and H. M. Moutsopoulos
Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study
Rheumatology,
May 1, 2004;
43(5):
626 - 632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Howe, A. Porwit-MacDonald, R. Wanat, R. Tehranchi, and E. Hellstrom-Lindberg
The WHO classification of MDS does make a difference
Blood,
May 1, 2004;
103(9):
3265 - 3270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kurzrock, H. M. Kantarjian, J. E. Cortes, N. Singhania, D. A. Thomas, E. F. Wilson, J. J. Wright, E. J. Freireich, M. Talpaz, and S. M. Sebti
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting
Blood,
December 15, 2003;
102(13):
4527 - 4534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Baum, J. Dullmann, Z. Li, B. Fehse, J. Meyer, D. A. Williams, and C. von Kalle
Side effects of retroviral gene transfer into hematopoietic stem cells
Blood,
March 15, 2003;
101(6):
2099 - 2113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Kantarjian
Treatment of Myelodysplastic Syndrome: Questions Raised by the Azacitidine Experience
J. Clin. Oncol.,
May 15, 2002;
20(10):
2415 - 2416.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. List
New Approaches to the Treatment of Myelodysplasia
Oncologist,
April 1, 2002;
7(90001):
39 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Stasi, M. Brunetti, E. Terzoli, and S. Amadori
Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes
Blood,
March 1, 2002;
99(5):
1578 - 1584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Steins, T. Padro, R. Bieker, S. Ruiz, M. Kropff, J. Kienast, T. Kessler, T. Buechner, W. E. Berdel, and R. M. Mesters
Efficacy and safety of thalidomide in patients with acute myeloid leukemia
Blood,
February 1, 2002;
99(3):
834 - 839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Greenberg, N. S. Young, and N. Gattermann
Myelodysplastic Syndromes
Hematology,
January 1, 2002;
2002(1):
136 - 161.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. D. Cheson, J. M. Bennett, H. Kantarjian, C. A. Schiffer, S. D. Nimer, B. Lowenberg, R. M. Stone, M. Mittelman, G. F. Sanz, P. W. Wijermans, et al.
Myelodysplastic syndromes standardized response criteria: further definition
Blood,
September 15, 2001;
98(6):
1985 - 1986.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Raza, P. Meyer, D. Dutt, F. Zorat, L. Lisak, F. Nascimben, M. du Randt, C. Kaspar, C. Goldberg, J. Loew, et al.
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
Blood,
August 15, 2001;
98(4):
958 - 965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Raza
Improve or abandon the standardized response criteria for myelodysplastic syndromes recommended by the International Working Group
Blood,
July 1, 2001;
98(1):
251 - 251.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma, L. Letendre, A. Tefferi, B. D. Cheson, J. M. Bennett, and P. L. Greenberg
Clarifications to the standard neutrophil response criteria for clinical trials in myelodysplastic syndromes are needed
Blood,
May 15, 2001;
97(10):
3321 - 3322.
[Full Text]
[PDF]
|
|
|
|
|
